Dimension Inx
Dimension Bio is a biotechnology company pioneering regenerative therapeutics. They design lifesaving solutions that restore organ function lost to disease, trauma, or aging. Their approach combines biology and engineering to create therapies that can restore or replace lost organ functions, with a focus on cell therapy, biomaterials, and tissue engineering. Their proprietary BioNidum™ system transforms cells into implantable, tissue-like therapies, promoting rapid vascularization and tissue integration. The company is based in Chicago, Illinois, and collaborates with biotech partners to develop regenerative products for high unmet clinical needs.
Industries
Nr. of Employees
small (1-50)
Products
Bioinspired cell-delivery platform (cell-delivery scaffold system)
A bioinspired scaffold system that combines engineered biomaterials and 3D-printed architectures to deliver high-density therapeutic cells, promote rapid vascularization, and enable tissue-like engraftment for regenerative indications such as liver failure and type 1 diabetes.
3D-printed porous synthetic bone graft (FDA-cleared 510(k))
A ready-to-use, flexible, 3D-printed synthetic bone graft composed of a porous composite of ceramic particles and biodegradable polymer designed for oral and maxillofacial reconstruction; cleared by FDA via 510(k).
Highly tunable porous biomaterial family for implantable constructs
Porous, mechanically robust materials engineered for handling and structural integrity that can be formed into complex constructs for regenerative applications.
Decellularized ECM-based absorbent sheet materials for surgical use
Thin, mechanically robust sheet materials derived from decellularized extracellular matrix designed to be absorbent and amenable to cutting, rolling, folding, or suturing for surgical applications.
Self-gelling hydrogel-enabled printable implant and injectable materials
Dry-form materials that are shelf-stable and gel on hydration to form interconnected hydrogel networks, enabling gel-laden, printable implants and injectable formulations for localization and stabilization in vivo.
Bioinspired cell-delivery platform (cell-delivery scaffold system)
A bioinspired scaffold system that combines engineered biomaterials and 3D-printed architectures to deliver high-density therapeutic cells, promote rapid vascularization, and enable tissue-like engraftment for regenerative indications such as liver failure and type 1 diabetes.
3D-printed porous synthetic bone graft (FDA-cleared 510(k))
A ready-to-use, flexible, 3D-printed synthetic bone graft composed of a porous composite of ceramic particles and biodegradable polymer designed for oral and maxillofacial reconstruction; cleared by FDA via 510(k).
Highly tunable porous biomaterial family for implantable constructs
Porous, mechanically robust materials engineered for handling and structural integrity that can be formed into complex constructs for regenerative applications.
Decellularized ECM-based absorbent sheet materials for surgical use
Thin, mechanically robust sheet materials derived from decellularized extracellular matrix designed to be absorbent and amenable to cutting, rolling, folding, or suturing for surgical applications.
Self-gelling hydrogel-enabled printable implant and injectable materials
Dry-form materials that are shelf-stable and gel on hydration to form interconnected hydrogel networks, enabling gel-laden, printable implants and injectable formulations for localization and stabilization in vivo.
Services
Collaborative projects with biotech and medical device partners to design, tune, and manufacture biomaterial solutions and scaffold architectures for specific therapeutic applications.
Collaborative projects with biotech and medical device partners to design, tune, and manufacture biomaterial solutions and scaffold architectures for specific therapeutic applications.
Expertise Areas
- Biomaterials engineering
- 3D bioprinting and additive manufacturing
- Tissue therapeutic platform development
- Cell therapy delivery and engraftment
Key Technologies
- 3D printing / additive manufacturing
- Controlled nano-/micro-/macro-architecture design
- Hydrogel and self-gelling material systems
- Decellularized ECM-derived materials
News & Updates
Dimension Inx was recognized for its Hyperelastic Bone® technology and the FDA-cleared CMFlex™ product, highlighting its innovation in regenerative medicine.
Dimension Bio participated in ringing the Nasdaq Bell in New York City, celebrating Chicago's innovation ecosystem.
The company rebranded from Dimension Inx to Dimension Bio, emphasizing its expanded vision in regenerative medicine.
The company secured $12 million in funding to develop and commercialize its regenerative products, including the FDA-approved CMFlex™.
The company expanded its patent portfolio with new patents on its biomaterials platform, including Fluffy-X™ and Tissue Papers™.
Recognized for Hyperelastic Bone® and the FDA-cleared CMFlex™ product, highlighting innovation in regenerative medicine.
Dimension Inx was recognized for its Hyperelastic Bone® technology and the FDA-cleared CMFlex™ product, highlighting its innovation in regenerative medicine.
Dimension Bio participated in ringing the Nasdaq Bell in New York City, celebrating Chicago's innovation ecosystem.
The company rebranded from Dimension Inx to Dimension Bio, emphasizing its expanded vision in regenerative medicine.
The company secured $12 million in funding to develop and commercialize its regenerative products, including the FDA-approved CMFlex™.
The company expanded its patent portfolio with new patents on its biomaterials platform, including Fluffy-X™ and Tissue Papers™.
Recognized for Hyperelastic Bone® and the FDA-cleared CMFlex™ product, highlighting innovation in regenerative medicine.